A new and refined injectable treatment for musculoskeletal disorders - bioscaffold properties of collagen and its clinical use. Part 3

Read Parts 1, 2

MD-KNEE 

• Gonarthrosis (in association with MD-POLY) 

• Knee pain secondary to rheumatoid arthritis or other autoimmune diseases (in association with MD-POLY) 

• Acute and chronic arthrosynovitis secondary to trauma, arthrosis and rheumatoid arthritis (in combination with MD-POLY) 

• Arthrosynovitis post-traumatic and post-surgical acute and chronic 

• Traumatic injuries or collateral ligament of the knee 

• Meniscus pain (in association with MD-POLY) 

• Preparation of meniscectomy surgery (in association with MD-MUSCLE) 

• Maintenance therapy after knee surgery (in association with MD-MUSCLE-NEURAL).

MD-SMALL JOINTS 

• Osteoarthritis of the hand fingers 

• Rhizoarthrosis of the thumb (Forestier’s disease) 

• Arthralgia caused bunion 

• Carpal tunnel syndrome (in association with MD-NEURAL) 

• De Quervain’s disease (in association with MD-NEURAL) 

• Simple metatarsalgia 

• Metatarsalgia associated with Morton’s neuroma (in association with MD-NEURAL) 

• Rheumatoid arthritis of the hand and foot (in association with MD-POLY) 

• Hand and foot tendinopathy secondary to prolonged immobilization (in association with MD-MATRIX). 

MD-ISCHIAL 

•Sciatica 

• Lumbar-sciatic pain (in association with MD-LUMBAR and MD-NEURAL) 

• Lumbar neuralgia (in association with MD-MUSCLE) 

• Sciatica after surgery for herniated disc L4-L5, L5-S1 (in association with MD-NEURAL)

• Morton’s neuroma (in association with MD-NEURAL). 

MD-POLY 

• Nonspecific diffuse pain (in association with MD-NECK or MD-THORACIC or MD-LUMBAR, and MD-NEURAL) 

• Costalsternalsyndrome (in association with MD-NEURAL) 

• Chronic polyarthritis secondary to autoimmune disease (eg, Systemic Lupus Erythematosus) (if the neuralgic symptoms prevail: in association with MD-NEURAL; if muscle symptoms prevail: in association with MD-MUSCLE) 

• Syndrome of “the broken bones” (if the neuralgic symptoms prevail: in association with MD-NEURAL; if muscle symptoms prevail: in association with MD-MUSCLE) 

• Joint pain secondary to viral disease (in association with other specific Guna MD)

• Joint pain secondary to cancer (eg, chronic leukemia, multiple myeloma) (in association with other specific district Guna MD).

MD-MUSCLE 

• Treatment of acute, subacute, chronic myofascial pain 

• Treatment of trigger points (in association with MD-NEURAL) 

• Treatment of referred pain areas (in association with MD-NEURAL) 

• Fibromyalgia (in association with MD-NEURAL and MD-MATRIX) 

• Dermatomyositis. 

MD-NEURAL

• Brachial nerve neuralgia secondary to cervical entrapment syndrome (in association with MD-NECK) 

• Persistent intercostal neuralgia (in association with MD-THORACIC) 

• Postherpetic neuralgia (in association with MD-THORACIC or MD-LUMBAR) 

• Atypical facial neuralgia (in association with MD-NECK and MD-TISSUE) 

• Trigeminal neuralgia (in association with MD-NECK and MD-MATRIX) 

• Pain of the temporomandibular joint (in association with MD-NECK) 

• Radicular neuritis of the cervical dorsal, lumbar, sacral spinal nerves, (respectively in association with MD-NECK, MD-THORACIC, MD-LUMBAR, and MD-ISCHIAL).

MD-MATRIX 

MD-MATRIX can be used alone or combined with any other MD of the same line, in order to create a personalized treatment based on the individual clinical picture. 

► MD-MATRIX can also be used in patients who need anti-aging topical treatment.

MD-TISSUE 

Also MD-TISSUE may be used alone or combined with any other MD of the same line, according to the individual clinical picture. 

► MD-TISSUE can also be used in patients who need anti-aging topical treatment.

 CONCLUSIONS

 With increasing age (Mays et Al., 1988), physical inactivity, intense physical activity or inadequate sports activity (Adam et Al., 1984), postural alterations, nutrient imbalances, changes of the PNEI axis, the connective tissue and the collagen in particular (real tissue protein) gradually detriorate and become inadequate at fulfilling their many specific functions. 

– The possibility to use in the praxis specific injections of Medical Devices (district and tissue MD) that replace the collagen deficiency always detectable in inflammatory and/or degenerative diseases of the locomotor apparatus and of other structures of mesodermal origin, injections that are easy to apply, natural, with no negative side effects, that can be associated with PRM (Physiological Regulating Medicine) therapies or homotoxicological or conventional local or systemic injective therapies in progress or planned and/or any physical therapy, provides an innovative and sophisticated tool for the prevention and treatment of the aging process of intra-articular and periarticular structures as well as structures of the nearby mesodermal support tissues. 

– The non-invasiveness of the injections with Guna MD, the first ones in this field having reported therapeutic results in 7 controlled clinical trials (Registration report at the High Institute of Health - Italy), as well as their other characteristics such as efficacy, tolerability, absence of allergic and natural reactions, makes this a unique and valuable tool in the specialistic and non specialistic praxis in improving the quality of life of patients who were intended - otherwise - to get worse or become chronic.